ema prac naion semaglutide very rare side effect june 2025 Meeting highlights from the Pharmacovigilance Risk Assessment Committee ( PRAC) 2-5 Does Ozempic Cause Blindness? [2026

GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone

Many patients transition to a maintenance cycle after the initial protocol period, with MOTS-c dosing spaced further apart to sustain the metabolic improvements achieved

For patients planning temporary therapy, the cost savings are substantial

[DOI] [PubMed] [Google Scholar] 39.Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, Monami M

Medication PA timelines are governed by existing Medicare Part D regulations and Medicaid statute, not CMS-0057-F

But for a recurring monthly cost, that effect is likely modest